Can AI help Biomunex find better bispecific antibody targets in cancer?
AI may speed cancer drug discovery, but Biomunex’s bigger test is whether smarter target pairing can translate into stronger immunotherapies.
Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?
Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.
Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Can Leads Biolabs turn Opamtistomig into a frontline EP-NEC treatment contender?
EP-NEC has no approved drug worldwide. Leads Biolabs now has to prove Opamtistomig can turn rare-tumor urgency into regulatory momentum.
Johnson & Johnson strengthens its multiple myeloma franchise with TECVAYLI and DARZALEX FASPRO approval. What clinicians are watching next
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.
Can Hemab Therapeutics’ sutacimig finally deliver the first preventive therapy for Glanzmann thrombasthenia after FDA breakthrough designation?
FDA grants Breakthrough Therapy Designation to Hemab Therapeutics’ sutacimig for Glanzmann thrombasthenia. Discover what this means for bleeding disorder treatment.
What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
What the Invenra B-Body licensing deal changes for Twist Bioscience and antibody discovery services
Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.
Why Janux Therapeutics’ JANX011 trial could redefine immune reset in autoimmune disease
Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.